Currently, regulatory approaches to nanotechnology are often based on existing laws and guidelines that have been adapted to account for the unique challenges posed by nanomaterials. For example, the FDA has issued guidance documents on the use of nanotechnology in drug products, while the EPA has developed the Nanoscale Materials Stewardship Program to gather information on the potential risks of nanomaterials.
